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Abstract
Ulcer disease in excluded segments after Roux-Y gastric bypass (RYGB) is rare but can evolve into a life-threatening situation.
The excluded segments exhibit a different behavior from that of non-altered anatomy; perforated ulcers do not result in pneu-
moperitoneum or free fluid, and therefore must bemet with a low threshold for surgical exploration. The anatomical changes after
RYGB impede routine access to the remnant stomach and duodenum. There are various options to address bleeding or perforated
ulcers. While oversewing and drainage preserves the anatomy and forgoes resection, remnant gastrectomy offers a definitive
solution. The importance of traditional risk factors such as smoking or use of non-steroidal anti-inflammatory drugs is unclear.
Eradication of Helicobacter pylori and secondary prophylaxis with proton-pump inhibitors is advisable, albeit in double-dose.
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Introduction
Bariatric surgery is the most effective treatment for morbid
obesity and results in sustained weight loss and resolution of
comorbidities. Over the past decades, the number of per-
formed bariatric operations has been on a constant rise,
reaching more than half a million procedures a year world-
wide [1]. This number is expected to increase even further, as
metabolic surgery is advocated as a treatment option for type 2
diabetes mellitus (T2DM) in patients with a body mass index
(BMI) < 35 kg/m2 [2].
Roux-en-Y gastric bypass (RYGB) is one of the most com-
monly performed procedures, is seen by many as the gold
standard treatment in patients with preexisting gastroesopha-
geal reflux disease, and is suggested as the first-choice proce-
dure for patients with T2DM [1]. After the creation of a small
gastric pouch, food is diverted away from the stomach directly
into the small bowel, and acid produced in the remnant stom-
ach will no longer reach the esophagus anymore. These dis-
tinctive changes in anatomy are thought to be key factors for
sustained weight loss. However, they also result in the down-
sides of this procedure, above all hindering access to the bil-
iary tree, the remnant stomach, and the duodenum [3–5].
Apparent peptic ulcer disease (PUD) in the excluded
stomach or duodenum is rare but leads to severe mor-
bidity and can be life-threatening. The anatomical
changes post-RYGB lead to a different clinical
presentation in an altered pathophysiological environ-
ment [6]. Whereas there are extensive data on marginal
u lce ra t ion (MU)—ulce rs a t the gas t ro - je juna l
anastomosis—experience with ulceration in the excluded
segments, especially in regard to treatment and preven-
tion, is mostly limited to small series and case reports
[6–28]. Therefore, this review aims to summarize the
available data, to contrast existing guidelines to the
altered situation post-RYGB and provide treatment
recommendations.
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Materials and Methods
All studies reporting ulcer formation in the excluded segments
of post-RYGB patients were considered eligible. A
MEDLINE search was performed during May 2020. The
search terms applied are listed in Table 1. In addition, the
reference list of articles retrieved by the search was assessed
for further publications. Titles and abstracts of publications
were screened by the primary author GP. Full texts of possibly
relevant studies were evaluated to determine eligibility.
All eligible articles were reviewed by the corresponding
author YB and co-author PN. Consensus among authors
was made regarding decisions to exclude articles. Non-
English articles were also excluded. The PRISMA flow
diagram is presented in Fig. 1 [29].
The following data were collected: age, sex, time since
the bariatric procedure, potential risk factors (smoking
behavior, NSAIDs, HP), clinical presentation, radiological
findings, site of affection, treatment, outcome, and
duration of follow-up.
Incidence and Presentation
The true incidence of PUD after RYGB is not known, and the
reported cases are certainly biased towards complicated PUD,
such as bleeding and perforation.
Here, we summarize reports of 54 patients in 5 case series
and 18 case reports (tbl1, tbl2) [6–28]. Thirty-five (65%) of
these individuals were female with an age ranging from 21 to
74 years. The interval between surgery and the onset of symp-
toms varied between 2.5 months and 20 years (Table 2).
Fifteen patients (28%) presented with gastrointestinal bleed-
ing, whereas 38 patients (70%) had perforated ulcers. The site
of bleeding was the gastric remnant in 53% and the duodenum
in 47%; 34% of perforations were localized in the gastric
remnant and 66% were in the duodenum (Table 3). The lead-
ing symptom at presentation was epigastric or upper abdom-
inal pain. In cases of bleeding, melena, weakness, and anemia
were common findings. Patients with perforation presented
with signs of sepsis, such as hypotonia, tachycardia, fever,
and elevated leukocytes.
Pathophysiological Considerations
Gastrin Levels and Acid Production in the Excluded
Stomach
After RYGB, there is continued, although diminished, bas-
al, and stimulated acid excretion in the excluded stomach.
Gastrin levels are decreased after RYGB, yet the gastric
mucosa maintains its ability to respond to vagal and hor-
monal stimuli [30], thus preserving an acidic environment
[12, 30–32]. The amount of acid production is influenced
by the proportion of the parietal cell mass, partitioned by
surgery to the pouch and the distal stomach, a factor cer-
tainly influencing the development of MU [33–35]. In the-
ory, high transection increases acid production in the
excluded stomach and contributes to acid-related mucosal
injury in the antrum and duodenum [12, 31]. Furthermore,
post-RYGB, cellular hypertrophy of the gastric mucosa
occurs in the presence of a reduction in G cells, again
lowering gastrin production [36]. Additionally, in proton-
pump inhibitor (PPI)–treated mice with normal anatomy,
the resulting hypochlorhydria causes bacterial overgrowth
resulting in gastric inflammation [37].
Buffering Effect of Nutrients
After RYGB, there is no counteracting effect on the acid in the
antrum and duodenum as the ingested food bypasses the ex-
cluded segments. However, the exclusion of the duodenum
also leads to a reduced and desynchronized pancreatic secre-
tion as the strongest stimulus of bicarbonate secretion is the
duodenal presentation of nutrients. Furthermore, bile
refluxing into the gastric remnant also contributes to mucosal
injury [12, 21, 38, 31].
Role of PPI
In large database-driven studies, up to a quarter of post-
RYGB patients are on PPIs [39, 40]. There is an inter-
play between PPI intake and gastrin levels, and long-
term use leads to hypergastrinemia stimulated by a re-
duction in gastric acid secretion via somatostatin
Table 1 Search terms and retrieved results
Search set Terms Results
#1 “gastric bypass”[Title/Abstract] AND ulcer[Title/Abstract] NOT marginal[Title/Abstract] 151
#2 “gastric bypass”[Title/Abstract] AND perforation[Title/Abstract] NOT anastomosis[Title/Abstract] 115
#3 “gastric bypass”[Title/Abstract]) AND “gastrointestinal bleeding”[Title/Abstract] NOT anastomosis[Title/Abstract] 47
#4 “gastric bypass”[Title/Abstract]) AND “gastrointestinal hemorrhage”[Title/Abstract] NOT anastomosis[Title/Abstract] 14
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feedback [41]. RYGB results in altered gastric emptying,
reduction in intestinal absorption surface, and a change
in pH. This leads to pharmacokinetic changes where
PPIs, as lipophilic drugs, are absorbed to a lesser degree
[42]. As PPIs are degraded by luminal acid, they are
usually protected by a coating to prohibit premature ac-
tivation and enable later absorption in the small bowel
which again is altered. Likewise, opened PPI capsules
have a significantly better effect on MU healing than
intact capsules [43]. In line with these pharmacokinetic
changes, plasma concentrations of omeprazole metabo-
lites in patients after RYGB are significantly reduced
compared to the corresponding levels in pre-RYGB and
controls [30].
Other Risk Factors: NSAIDs, Smoking,H. pylori, and ZES
Nonsteroidal Anti-inflammatory Drugs
More than 30 million patients use NSAIDs on a daily basis
[44]. As unselective inhibitors of the cyclo-oxygenase pathway,
they deeply affect the gastric mucous barrier [44]. NSAID use
is a risk factor for PUD in the general population and for MU
after RYGB [45, 46]. In the long term, up to 40% of NSAID
users experience gastroduodenal ulcers [12].
In 40 of the 54 reported patients (74%), NSAID use was
stated. Surprisingly, only 6 of the 40 patients (15%) had a
history of NSAID use. Thus, other factors might have a higher
impact on ulcer formation.
Fig. 1 Flow diagram of study
selection [29]
OBES SURG
Table 2 Patient characteristics and risk factors (Y yes, N no, n/a not available, NSAIDs non-steroidal anti-inflammatory drugs)
Author [Ref] Patient characteristics Risk factors
Sex (F/M) Age (years) Time since operation (years) Smoking (Y/N) NSAIDs (Y/N) H. pylori
Andersen [7] 1/0 34 3 n/a N n/a
Arshava [11] 0/2 36 3 n/a Y n/a
54 0.2 n/a n/a n/a
Bjorkman [12] 0/1 24 6 n/a N n/a
Braley [13] 2/1 49 17 n/a n/a n/a
59 17 n/a n/a n/a
49 16 n/a n/a n/a
Dai [9] 1/0 54 5 N N neg
Eid [14] 0/1 61 10 N N n/a
Gypen [15] 1/0 35 0.2 n/a n/a pos
Husain [16] 1/0 63 1.5 n/a n/a n/a
Iranmannesh [28] 4/3 48 20 n/a Y empirical eradication
39 10 n/a N empirical eradication
61 7 n/a N empirical eradication
54 10 n/a N empirical eradication
40 13 n/a N empirical eradication
70 9 n/a N empirical eradication
45 16 n/a Y empirical eradication
Iskandar [17] 0/2 59 10 n/a N neg
37 n/a n/a N neg
Issa [18] 0/1 39 1.2 n/a N pos
Ivanecz [19] 0/1 59 2 N Y neg
Macgregor [20] 9/2 63 1.9 n/a N n/a
37 1.8 n/a N n/a
40 8 n/a N n/a
31 0.6 n/a N n/a
53 5 n/a N n/a
43 8 n/a N n/a
29 11 n/a N n/a
48 4 n/a N n/a
57 1.5 n/a N n/a
40 20 days n/a N n/a
56 12 n/a N n/a
Mittermair [21] 1/0 54 1.3 n/a n/a pos
Ovaere [10] 1/0 33 1.2 N N neg
Papasavas [22] 1/0 35 1 n/a n/a neg
Patrascu [8] 1/0 52 7 N N neg
Pohl [6] 2/0 46 6 N N neg
74 14 N N neg
Sasse [26] 1/1 55 1 n/a Y n/a
47 3.5 n/a Y n/a
Snyder [23] 4/2 53–67 1.5–6 n/a N 1 pos; 2 neg; 3 n/a
Spires [24] 0/1 48 4 n/a n/a n/a
Zagzag [27] 5/0 57 5 n/a n/a pos
54 12 n/a n/a pos
53 9 n/a n/a neg
47 0.7 n/a n/a n/a
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Smoking
There is wide evidence implicating smoking as a risk factor
for the occurrence, recurrence, and complications of PUD
[47]. Suggested mechanisms include increased gastric acid
secretion, altered gastric motility, a higher rate of
duodenogastric reflux, and impaired duodenal and pancreatic
bicarbonate secretion [47, 48]. Among patients with RYGB,
smoking seems to increase the risk for MU and especially
perforation [49]. Furthermore, ulcer healing is impaired in
smoking patients compared to non-smokers [49].
Smoking behavior was reported only for 8 patients (15%),
and none of them currently smoked.
Helicobacter pylori
HP (Helicobacter pylori) is one of the most common human
infections and plays a pivotal role in the development of gas-
tritis, ulcer formation, and malignant lesions [50–53]. Its prev-
alence in bariatric patients ranges up to 85%, yet data are
controversial and cover mostly MU [54]. Consequently, inter-
national guidelines differ in their recommendations for HP
screening and management in bariatric patients [55, 56].
Detection of HP in post-RYGB patients can be challeng-
ing; histological samples remain the gold standard. Urea
breath tests, especially in the absence of a pouch infection,
can be falsely negative, as most of the gastric mucosa will
not be in direct contact with urea [15]. Serology is of less
diagnostic value since complete resolution of elevated IgG
antibody titers after treatment of HP infection is not common,
even though negative IgG antibodies can exclude HP [50, 57].
With a sensitivity and specificity over 90%, monoclonal stool
antigen tests are probably the most suitable non-invasive di-
agnostic tool [50, 57].
Reported data provided the HP status for 20 of 54 patients
(37%). Based on histological findings, 7 (15%) were positive.
However, 7 more were eradicated empirically. Given the un-
known influence of HP on the development of PUD after
RYGB, its role as the most common proven risk factor for
gastric cancer, and impaired access to the excluded stomach
and duodenum for surveillance, patients should be screened
preoperatively unless further data are available [55, 56].
Additionally, biopsies should be taken in revisional cases.
Zollinger-Ellison Syndrome (ZES)
ZES (Zollinger-Ellison syndrome) is a rare condition in
which gastrin-secreting neuroendocrine tumors cause el-
evated acid production from gastric parietal cells, thus
leading to recurrent peptic ulcers. Approximately 75%
of ZES are sporadic, whereas 25% are associated with
multiple endocrine neoplasm type 1. There is a single
case report of a patient with recurrent gastrojejunal
anastomotic strictures and MU following RYGB due to
a gastrinoma of the duodenum [58]. The role of ZES is
negligible but should be considered in cases of multiple
recurrent or refractory ulcers.
Gastrointestinal Motility: Gastroparesis/Stasis
Gastroparesis can occur following planned or inadvertent
vagotomy [59]. Its incidence after partial gastrectomy is up
to 5% [60]. Changes in ghrelin secretion influence gastric
motility [60, 61]. Bile reflux into the gastric remnant is
observed in 36% of post-RYGB patients, and its deleteri-
ous effects on the mucosal barrier lead to chronic gastritis
and intestinal metaplasia and may contribute to the forma-
tion of ulcers [62, 63].
Furthermore, delayed emptying and stasis in the
biliopancreatic limbmay predispose patients to bacterial over-
growth followed by inflammatory changes in the intestinal
wall potentially leading to ulceration [64].
Diagnosis
Incidence of Gastritis and Predictors of PUD
Studies evaluating the gastric remnant after RYGB are rare.
Among 53 patients with RYGB, remnant gastritis was found in
87% of patients with a normal mucosa in the pouch, indicating a
harmful effect of unbuffered acid on the gastric remnant [31].
Elsewhere, inmore than half of patients taking PPI, endoscopy of
the gastric remnant revealed peptic changes [30].
Considering symptoms as surrogates for gastritis and PUD,
upper abdominal pain by far is the most frequent symptom
leading to readmissions after RYGB [65]. Of the reported
Table 2 (continued)
Author [Ref] Patient characteristics Risk factors
Sex (F/M) Age (years) Time since operation (years) Smoking (Y/N) NSAIDs (Y/N) H. pylori
35 2 n/a n/a neg
Zerey [25] 0/1 57 12 N N n/a
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Table 3 Presentation, treatment, and outcomes
Author n Presentation Location Treatment Outcome Follow-up
Andersen [7] 1 Perforation Gastric remnant Ulcer excision, bypass take down Cured 9 days
Arshava [11] 2 Perforation Gastric remnant Remnant gastrectomy Cured 6 months
Perforation Gastric remnant Remnant gastrectomy, pancreas preserving duodenal resection Cured n/a
Bjorkman [12] 1 Perforation Duodenum Remnant gastrectomy, duodenal stump oversewing Cured n/a
Braley [13] 3 Bleeding Duodenum Remnant gastrectomy, resection of first portion of duodenum Cured 24 months
Bleeding Gastric remnant Remnant gastrectomy Cured 12 months
Bleeding Gastric remnant Remnant gastrectomy Cured 9 months
Dai [9] 1 Perforation Gastric remnant Oversewing, omental patch, gastric tube placement Cured 4 weeks
Eid [14] 1 Bleeding n/a Angiography, coiling Cured n/a
Gypen [15] 1 Perforation Duodenum Oversewing, omental patch Cured 6 months
Husain [16] 1 Bleeding Duodenum Remnant gastrectomy, resection of first portion of duodenum Cured n/a
Irannmanesh [28] 7 Perforation Gastric remnant Oversewing, omental patch Cured 12 days
Perforation Gastric remnant Oversewing, omental patch Cured 3 days
Perforation Gastric remnant Oversewing, omental patch, gastrostomy Cured 8 dyas
Necrosis Gastric remnant Remnant gastrectomy Cured 8 days
Bleeding Gastric remnant Enteroscopy with local hemostasis Cured 5 days
Bleeding Gastric remnant conservative Cured 3 days
Bleeding Gastric remnant Enteroscopy with local hemostasis Cured 3 days
Iskandar [17] 2 Perforation Duodenum Oversewing Cured 1 week
Perforation Duodenum Duodenostomy, drainage Cured n/a
Issa [18] 1 Bleeding Duodenum Laparoscopic gastroduodenoscopy, electrocoagulation Cured 10 months
Ivanecz [19] 1 Bleeding Duodenum Remnant gastrectomy, resection of first portion of duodenum Cured 3 months
Macgregor [20] 11 Perforation Duodenum Oversewing, subsequent remnant gastrectomy Cured n/a
Perforation Gastric remnant Oversewing and gastrotomy, subsequent remnant gastrectomy Cured n/a
Perforation Duodenum Oversewing Cured n/a
Perforation Duodenum Oversewing, and gastrotomy, subsequent remnant gastrectomy Cured n/a
Perforation Duodenum Oversewing, vagotomy, pyloroplasty Cured n/a
Perforation Duodenum Oversewing, subsequent remnant gastrectomy Cured n/a
Perforation Duodenum Oversewing, subsequent remnant gastrectomy Cured n/a
Perforation Duodenum Oversewing, subsequent remnant gastrectomy Cured n/a
Perforation Gastric remnant, Oversewing, subsequent remnant gastrectomy Cured n/a
Perforation Duodenum Oversewing, subsequent remnant gastrectomy Cured n/a
Perforation Duodenum Gastrostomy, subsequent remnant gastrectomy Cured n/a
Mittermair [21] 1 Perforation Duodenum Oversewing Cured 6 days
Ovaere [10] Perforation Gastric remnant Oversewing, omental patch Cured n/a
Papasavas [22] 1 Perforation Gastric remnant Remnant gastrectomy Cured 38 months
Patrascu [8] Bleeding Gastric remnant Remnant gastrectomy Cured 2 months
Pohl [6] 2 Perforation Duodenum Oversewing, omental patch Cured 3 years
Perforation Duodenum Oversewing, omental patch Cured 3 years
Sasse [26] 2 Perforation Gastric remnant Oversewing, omental patch Cured 2 years
Perforation Gastric remnant Intraoperative death Death
Snyder [23] 6 4 perforation 4 duodenum 5 remnant gastrectomy 5 Cured 2–4 years
2 Bleeding 2 Gastric remnant 1 duodenal oversewing 1 Death
Spires [24] 1 Bleeding Duodenum Remnant gastrectomy Cured 6 months
Zagzag [27] 5 Perforation Duodenum Graham patch Cured n/a
Perforation Duodenum Graham patch Cured n/a
Perforation Duodenum Graham patch Cured n/a
Perforation Duodenum Graham patch Cured n/a
Perforation Duodenum Graham patch Cured n/a
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patients, over two-thirds reported epigastric and/or upper ab-
dominal pain.
Free Air: Plain X-ray and Abdominal CT
With a sensitivity of approximately 86% in detecting gastro-
intestinal perforation, CT is widely accepted as accurate in the
evaluation of such patients [66]. However, in post-RYGB
patients, the presence of free intra-abdominal air due to perfo-
ration of the excluded segments is much less common if not
absent. Patients with perforation had plain X-rays in 20 of 41
cases (49%), and free air was detected in two patients. When
performed, 44% of CT scans showed free intra-abdominal air.
Thus, in patients after RYGB, negative CT findings do not
exclude a viscus perforation, and operative exploration should
be performed with a low threshold. Indeed, the presence of
free air and even more fluid should raise suspicions about a
pouch-gastric fistula or irregularities at the level of the jejuno-
jejunal anastomosis [6, 15, 20, 67].
Bleeding: CT and Mesenteric Angiography
The sensitivity and specificity of CT angiography for active
gastrointestinal bleeding are over 90%. However, its sensitiv-
ity for obscure bleeding is only approximately 45% [68]. Even
though it lacks therapeutic options, CT angiography provides
essential information regarding the bleeding origin and allows
for subsequent mesenteric angiography to be targeted to an
area of interest leading to an improved angiographic detection
rate. The technical success rate of transarterial embolization in
gastrointestinal bleeding is reported to be up to 93% with a
rate of bleeding cessation up to 81% [69].
Among the reported cases of ulcer bleeding following
RYGB, only indirect signs but no active bleeding were detect-
ed.Mesenteric angiography without previous CT angiography
was performed in 25% of patients, and angiography
showed active bleeding in 67% of patients. One patient
had successful embolization, whereas embolization
failed in the other patient, and surgical intervention
was needed to control bleeding [14, 25].
Transarterial angiography with subsequent embolization is an
option to address bleeding in those patients. This procedure is non-
invasive and has a high success rate [69]. However, in a general
context, it might be more purposeful to address such patients sur-
gically, or rather endoscopically via temporary gastrostomy.
Access to the Excluded Segments: Double-Balloon
Endoscopy, Intraoperative Temporary Gastrostomy,
and Pouch Gastrostomy
There are various ways to access the excluded segments post-
RYGB. Upper endoscopy is considered a first-line approach for
the diagnosis and treatment of upper gastrointestinal bleeding
and provides a valid alternative in the treatment of postbariatric
complications such as leaks or anastomotic bleeding [70].
Whereas gastro-jejunal anastomoses can easily be evaluated,
the combined length of alimentary and biliopancreatic limbs
complicates access to the gastric remnants and duodenums.
With the use of a pediatric colonoscope, the remnant can be
reached in up to 68% of cases [31]. This rate can be raised to
88% by applying a double-balloon technique albeit with a higher
perforation rate of 10% [71].
Eleven (20%) of the reported patients underwent a standard
upper endoscopy, which was non-diagnostic in every case. In 5
patients, retrograde endoscopy was attempted; the remnant was
reached in three patients, and treatment of the bleeding was suc-
cessful in two patients [12, 14, 22, 28]. Thus, in time-critical
situations, conventional upper endoscopy can rule out patholo-
gies of the gastric pouch, anastomosis, and alimentary limb, but
its diagnostic value in assessing the excluded segments is limited.
Access to the excluded segments can further be achieved with
percutaneous transgastric endoscopy. CT or ultrasonographic
guidance to introduce a guidewire is followed by placement of
a gastrostomy tube into the remnant stomach. Serial dilations of
the gastrostomy over several weeks are then required until an
endoscope can be introduced. This technique is safe and effective
but obviously not suitable for emergency situations [4, 5, 62].
Intraoperative transgastric endoscopy allows for addressing
or excluding other pathologies at the same time [72]. Usually,
access to the gastric remnant is established during laparoscopy
via temporary remnant gastrostomy [72]. Among the
reviewed patients with ulcer bleeding or perforation after
RYGB, 8 of 54 had (15%) intraoperative transgastric endos-
copy [13, 18, 25, 28]. Endoscopy revealed duodenal ulcers in
3 cases and gastritis and benign ulcers in 2 cases.
Treatment and Follow-Up
There are various options to address complicated PUDs.
The main goal is to resolve septic foci and provide a
Table 3 (continued)
Author n Presentation Location Treatment Outcome Follow-up
Zerey [25] 1 Bleeding Duodenum Duodenotomy, oversewing Cured 5 days
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solution for future follow-up in this special anatomic
situation at the same time.
Gastrectomy Versus Oversewing Ulcers
As patients with PUD after RYGB are more likely to be diag-
nosed with complicated PUD, the treatment is generally oper-
ative. There are several controversial issues, such as whether
to perform remnant gastrectomy, ulcer repair with concomi-
tant vagotomy, or mandatory intraoperative gastroscopy. In
the case of free air or fluid, assessing the patency of the
jejuno-jejunostomy is mandatory [67].
The recurrence rate of PUD determines the extent of sur-
gery needed. So far, the paucity of data and the rather short
follow-up overall do not allow for general recommendations.
Although remnant gastrectomy seems drastic, it certainly fa-
cilitates the follow-up and most effectively counteracts PUD
unless there is ectopic gastric tissue elsewhere. In the case of
perforated PUD, oversewing after biopsies is an option. It is
certainly advisable to enable easier future access to the rem-
nant stomach, especially when intraoperative gastroscopy is
not performed at the time of the procedure. (Super)selective
vagotomy may be added to reduce acid production.
Of 54 described cases, 50 (93%) underwent surgery. In
48% of these patients, remnant gastrectomy was performed,
combined with resection of the first portion of the duodenum
in 6% and pancreas-preserving duodenal resection in 2%.
Oversewing or Graham patches were performed in 37% of
patients. Other procedures included ulcer excisionwith bypass
reversal, duodenostomy with drainage, coagulation by intra-
operative endoscopy, and angiographic coiling (tbl 2).
In a short-term follow-up, 94% of patients were cured, one
needed reoperation because of early postoperative bleeding
following remnant gastrectomy with resection of the first part
of the duodenum, and two patients died, one from pulmonary
complications and the other one intraoperatively due to
multiorgan failure.
There is a wide variety in the duration of follow-up,
ranging from 5 days to 4 years and only limited data
are available overall.
Follow-Up: Secondary Prophylaxis, Cancer Risk
Postoperative eradication of HP was routine for positive
patients. Secondary prophylaxis with PPIs was initiated
in 23 of 54 patients (of whom one had a remnant gas-
trectomy), with varying durations, from 2 weeks to life-
long. Meta-analytic data suggest a significant benefit of
prophylactic PPI in reducing MU after RYGB [73].
Despite lacking evidence, PPI may therefore be consid-
ered to counteract recurrent PUD in the excluded
segments.
Cancer in the remnant stomach is rare; a meta-analysis
found 17 patients who reported with pain, abdominal disten-
sion, and weight loss as main symptoms [74].
Conclusion
PUD in the excluded segments post-RYGB is rare but life-
threatening. The presentation of perforated PUD is different
from that in non-bariatric patients, as the usual signs, such as
free air, may not be present. Access to the excluded segments
is impaired; in time-critical situations, temporary gastrostomy
during laparoscopy is a viable option. Remnant gastrectomy is
a definitive solution that forgoes the need for further endo-
scopic follow-up. Scarce available data do not allow for any
conclusion about the role of potential risk factors; however,
HP should be eradicated. Secondary prophylaxis with PPI
should be administered in increased dosage due to altered
absorption post-RYGB.
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